Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab DDI Study with CYP Substrates in Psoriasis
NCT02772601Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc. Primary endpoints: Area under the concentration-time curve of caffeine, Area under the concentration-time curve of warfarin and 4 more. Started Sep 2016; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02772601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772601.